Table 2. Direct and indirect costs before and during TB treatment by case finding approach (in USD).

Cost category		ACF						PCF						p-value†
		Median	[IQR]	Mean	(SD)	[Range]	% total mean	Median	[IQR]	Mean	(SD)	[Range]	% total mean
Before treatment	Direct	2.5	[1.2–11]	12.4	(26.5)	[0–210]	3.1%	14.8	[2.2–47.3]	57.4	(136.8)	[-9.2–891]	10.7%	<0.001*
	Indirect	0	[0–4.1]	18.6	(58.8)	[0–471.4]	4.7%	1.4	[0–4.1]	59.1	(325.9)	[0–3069]	11.0%	0.073
During treatment	Direct	66.8	[22–122.6]	98.1	(105.9)	[0–562.8]	24.6%	90	[45–202.5]	148.3	(182.4)	[0–1311]	27.7%	0.014*
	Indirect	85.1	[0–450]	269.8	(361.4)	[0–1365]	67.6%	60	[0–382.5]	270.2	(405.3)	[0–1625]	50.5%	0.553
Total		240.7	[65.5–594.6]	399	(416)	[6.5–1649]	100.0%	290.5	[113.6–813.4]	534.9	(627.8)	[10.8–4251]	100.0%	0.104

^* Significant difference (P<0.05)

^† Wilcoxon rank-sum test

IQR: Interquartile range, SD: Standard deviation. A number with a negative value of less than zero is due to insurance reimbursement.